ICTCAR-052

N/A

Report date: 2024/07/22 10:26:21

Base Information

Drug NameICTCAR-052
Drug Alias NameAnti-MUC 1 CART cell therapyMUC-1 CAR T cellAnti MUC 1 chimeric antigen receptor T cell therapy (Innovative Cellular)ICTCAR-052
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-MUC1
TargetsMucin-1
Therapy Area/IndicationsLung NeoplasmsPancreatic NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesInnovative Cellular Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnovative Cellular Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsLung NeoplasmsPancreatic NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A